Response to Eribulin in a Difficult-To-Treat Triple Negative Breast Cancer Patient-Juniper Publishers



In this paper, we report our experience with eribulinmesylate in a locally advanced triple negative breast cancer (BC) patient who was treated with antracyclines and taxanes, and became metastatic. After one refractory line with Capecitabine and Bevacizumab, there was response to Eribulin. No unexpected acute toxicity was observed.

https://juniperpublishers.com/ijcsmb/IJCSMB.MS.ID.555559.php


For more Open access journals please click on JuniperPublishershttps://juniperpublishers.com/



Comments

Popular posts from this blog

Undifferentiated Carcinoma of the Larynx in a Developing Community- Juniper Publishers

The Oleaginous Rucksack-Steacystoma Multiplex-Juniper Publishers

Squamous Cell Carcinoma of The Tongue in A Developing Community- Juniper publishers